Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.79 and traded as high as $0.92. Brainstorm Cell Therapeutics shares last traded at $0.90, with a volume of 7,113 shares trading hands.
Brainstorm Cell Therapeutics Stock Down 2.0%
The stock’s fifty day moving average price is $0.92 and its two-hundred day moving average price is $0.79. The company has a market capitalization of $10.01 million, a PE ratio of -0.27 and a beta of 0.23.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Further Reading
- Five stocks we like better than Brainstorm Cell Therapeutics
- Financials Hit Record Highs as the AI Trade Unravels—Can They Keep Leading?
- Netflix’s Big Sell-Off May Be Sending the Wrong Signal
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
